Oncolytics Biotech Inc.
Oncolytics Biotech Inc. Fundamental Analysis
Oncolytics Biotech Inc. (ONCY) shows moderate financial fundamentals with a PE ratio of -3.51, profit margin of 0.00%, and ROE of 51.32%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 47.5/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ONCY's fundamental strength across five key dimensions:
Efficiency Score
WeakONCY struggles to generate sufficient returns from assets.
Valuation Score
ExcellentONCY trades at attractive valuation levels.
Growth Score
ModerateONCY shows steady but slowing expansion.
Financial Health Score
ExcellentONCY maintains a strong and stable balance sheet.
Profitability Score
WeakONCY struggles to sustain strong margins.
Key Financial Metrics
Is ONCY Expensive or Cheap?
P/E Ratio
ONCY trades at -3.51 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ONCY's PEG of -0.25 indicates potential undervaluation.
Price to Book
The market values Oncolytics Biotech Inc. at -23.93 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -3.25 times EBITDA. This is generally considered low.
How Well Does ONCY Make Money?
Net Profit Margin
For every $100 in sales, Oncolytics Biotech Inc. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $51.32 in profit for every $100 of shareholder equity.
ROA
Oncolytics Biotech Inc. generates $-4.28 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.25 in free cash annually.
FCF Yield
ONCY converts -26.18% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-3.51
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.25
vs 25 benchmark
P/B Ratio
Price to book value ratio
-23.93
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.10
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.38
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
51.32
vs 25 benchmark
ROA
Return on assets percentage
-4.28
vs 25 benchmark
ROCE
Return on capital employed
-11.32
vs 25 benchmark
How ONCY Stacks Against Its Sector Peers
| Metric | ONCY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -3.51 | 28.65 | Better (Cheaper) |
| ROE | 5132.04% | 795.00% | Excellent |
| Net Margin | 0.00% | -49787.00% (disorted) | Weak |
| Debt/Equity | -0.10 | 0.40 | Strong (Low Leverage) |
| Current Ratio | 1.38 | 3.73 | Neutral |
| ROA | -428.40% | -20255.00% (disorted) | Weak |
ONCY outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Oncolytics Biotech Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
27.87%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
61.65%
Industry Style: Defensive, Growth, Innovation
High Growth